CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy
Authors
Keywords
-
Journal
JOURNAL OF IMMUNOLOGY
Volume 197, Issue 1, Pages 179-187
Publisher
The American Association of Immunologists
Online
2016-05-24
DOI
10.4049/jimmunol.1600146
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
- (2015) A. Lo et al. CANCER RESEARCH
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages
- (2015) Gregory L. Beatty et al. GASTROENTEROLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage
- (2015) José Medina-Echeverz et al. Cancer Immunology Research
- Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
- (2015) R. Winograd et al. Cancer Immunology Research
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice
- (2014) Annie Mirsoian et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma
- (2014) D. L. Bajor et al. Cancer Immunology Research
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy
- (2013) Myriam N. Bouchlaka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
- (2012) Kristopher K. Frese et al. Cancer Discovery
- Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
- (2011) M. F. Fransen et al. CLINICAL CANCER RESEARCH
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Microvascular thrombosis and CD40/CD40L signaling
- (2010) F. N. E. GAVINS et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started